Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator dshade, joboggi, Sir Francelote, zoomboom, Rosym
Search This Board:
Last Post: 11/24/2014 2:59:03 AM - Followers: 713 - Board type: Free - Posts Today: 4

                                 
                Amarantus BioScience Holdings, Inc.

   Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
   The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
   The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
   The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

For further information, please visit www.Amarantus.comor connect with the company on FacebookTwitter, LinkedIn & Google+



            

 
PRESS RELEASES & NEWS ARTICLES

Amarantus Completes Enrollment of Expanded LP-002 Study of Alzheimer's Blood Diagnostic LymPro Test(R) to Assess Predictive Value in Early-Stage Disease
Nov. 20, 2014
Astute Deal Brings In Another Shot On Goal For Amarantus Bio
By Jason Napodano, CFA -  November 19, 2014
Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc.
Nov 19, 2014    12:46 p.m.     
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza

Nov 17, 2014    4:20 p.m.
Amarantus to Host Business Update Conference Call on November 18, 2014
Nov 17, 2014    8:02 a.m. 
Amarantus Reports Third Quarter 2014 Financial Results and Enters Into Strategic Preferred Financing
Nov 10, 2014    6:01 a.m. 
AMARANTUS BIOSCI INC(OTCMKTS:AMBS) is Making Moves 
OCTOBER 29, 2014 
Eltoprazine, LymPro and MANF: The Path Forward to Value Creation
 October 27, 2014    8:00 am
Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees
Oct 20, 2014 8:01 a.m.
Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Also in Cramer's Portfolio: Amarantus Applies To FDA For MANF Orphan Drug Designation In Retinitis Pigmentosa 

Oct 16, 2014   9:30 a.m.
Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R)
Oct 9, 2014    6:01 a.m.
Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
Oct 7, 2014    8:01 a.m.
Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024 : Opportunities for Leading Companies
Oct 1, 2014    9:16 p.m.
Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
Sept 29, 2014     2:04 p.m.

 

Amarantus BioScience (Documentary Trailer)

Oct. 19, 2014
SNNLive - Amarantus  BioScience Holdings, Inc.
  Published on June 21, 2014


    
 
 
    
       

 

Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland

info@amarantus.com
pr@amarantus.com


Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
.

408-737-2734 x101
ir@amarantus.com







 
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols


Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179

           
info@vstocktransfer.com

www.VStockTransfer.com 


 
 
smiley  Amarantus expects to announce the full results of its in-depth analysis of the full mild-to-severe AD cohort of 140 subjects (initial 72 patients + 68 patient extension) by year-end 2014, and make a final determination on which assay conditions (Version 1 vs. Version 2) it will use to support its product launch.   cool

smiley  "Amarantus is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong. "Today's data gives us all the information we need to move full steam ahead with this strategy. We can now tailor our initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. We have nearly completed assembling the resources needed to launch LymPro to the RUO community by the year-end 2014. Thereafter, we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B"
 
   Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen” 
 
 
smiley   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above – for the end of 2014 alone – will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Current Report Filing (8-k) 06:07 AM
AMBS News: Statement of Changes in Beneficial Ownership (4) 11/20/2014 01:17:24 PM
AMBS News: Statement of Changes in Beneficial Ownership (4) 11/20/2014 12:28:34 PM
AMBS News: Current Report Filing (8-k) 11/17/2014 05:24:20 PM
AMBS News: Small Company Offering and Sale of Securities Without Registration (d) 11/17/2014 05:03:16 PM
News News Alert: Current Report Filing (8-k) 11/24/2014 06:07:58 AM
PostSubject
#109587  Sticky Note JN - Why I'm Still Optimistic On LymPro Rosym 10/25/14 09:00:15 AM
#108674  Sticky Note Update from ASM Meeting: Sir Francelote 09/23/14 08:44:23 AM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#110001   Thanks Iron Heart.!! GS1 11/24/14 02:59:03 AM
#110000   Gerald will be making hudreds of millions in GS1 11/24/14 02:45:37 AM
#109999   Excellent news folks !!! GS1 11/24/14 02:32:33 AM
#109998   Thoughts on comparison, if any" between GEDi test dh4systems 11/24/14 01:18:13 AM
#109997   Gerald is buying shares in open market and GS1 11/23/14 11:58:39 PM
#109996   4 reasons to think the PPS is headed brharris 11/23/14 09:06:20 PM
#109995   Nice post GS1! Iron heart 11/23/14 02:23:35 PM
#109994   I love it when a plan comes together. sante1 11/23/14 10:31:36 AM
#109993   FDA comment on Amyvid GS1 11/23/14 03:25:51 AM
#109992   Thanks for the link and good post too. Titan V 11/23/14 02:28:39 AM
#109991   No doubt there will be handful of them GS1 11/23/14 12:21:03 AM
#109990   You guys have no idea how big this GS1 11/23/14 12:07:01 AM
#109989   I gonna believe more and more that Gerald's sante1 11/22/14 08:30:44 PM
#109988   Correct. You a staying projected value once trails brharris 11/22/14 03:31:31 PM
#109987   note that .075 was a good entry point. joboggi 11/22/14 02:00:30 PM
#109985   ESS valued at 500 million and AMBS paid GS1 11/22/14 12:33:04 PM
#109984   Thanks for posting the chart. It's really starting brharris 11/22/14 12:14:14 PM
#109983   Yes sir. It shows that money is flowing brharris 11/22/14 12:12:59 PM
#109981   stockcharts.com/c-sc/sc?s=AMBS&p=D&b=5&g=0&i=t65601300984&r=1416675445397[/ GS1 11/22/14 11:59:29 AM
#109980   When stock price is going down but Money Titan V 11/22/14 11:58:06 AM
#109979   So what does this do to the stock. http://www.cnbc.com/id/102200036 brianc22 11/22/14 11:46:21 AM
#109978   Lonza invested 8-10 million to develope PermaDerm and GS1 11/22/14 11:34:24 AM
#109976   After eighteen months of DD they decided to GS1 11/22/14 11:23:59 AM
#109975   ESS is currently valued at twice what AMBS brharris 11/22/14 11:21:11 AM
#109974   GC should stop making others rich (preferably companies, dsw 11/22/14 11:05:21 AM
#109973   ~AMBS KEY HIGHLIGHTS GS1 11/22/14 10:57:27 AM
#109972   Diabetes/Wolfram - AMBS's MANF zoomboom 11/22/14 10:56:30 AM
#109971   When Gerald pulled trigger on Reginicin and Lonza GS1 11/22/14 10:15:07 AM
#109968   As for Eltoprazine : We should get news GS1 11/22/14 02:28:48 AM
#109967   GREAT NEWS FOLKS.... GS1 11/22/14 01:38:02 AM
#109966   AMBS NEWS OUT GS1 11/22/14 01:34:19 AM
#109963   The ODD for MANF was submitted in Oct. joboggi 11/21/14 08:25:36 PM
#109960   Maybe but maybe not. The news of insider Angry Goat 11/21/14 04:17:17 PM
#109959   This spam is a violation and should be brharris 11/21/14 03:08:57 PM
#109956   Why? Did you file a complaint? myersvodka 11/21/14 02:27:57 PM
#109954  Restored This SCAM not suspended yet? Sgt. Pepper 11/21/14 02:08:44 PM
#109953   Looks like we could see a gap up brharris 11/21/14 09:28:37 AM
#109952   Interesting to know sante1 11/21/14 01:33:37 AM
#109950   Zoom..The IP is important..What makes it an issue guardiangel 11/20/14 11:24:28 PM
#109949   To all who are open minded to connections..William guardiangel 11/20/14 10:57:55 PM
#109948   Trademark is just that. Trademark the name. zoomboom 11/20/14 10:41:03 PM
#109947   The trademark is no issue if GC is guardiangel 11/20/14 10:32:46 PM
#109946   Can you imagine how much the conversation here brharris 11/20/14 09:37:15 PM
#109945   The trademark is no issue here. zoomboom 11/20/14 09:33:12 PM
#109944   The post was from zoomboom: http://investorshub.advfn.com/boards/read_msg.aspx? Rosym 11/20/14 09:32:45 PM
#109943   Earth shattering AMBS prediction. Impressive. zoomboom 11/20/14 09:29:13 PM
#109942   My feeling is Gerald wants to make a myersvodka 11/20/14 09:12:56 PM
#109941   Bell Cow..The ? was asked but the explanation guardiangel 11/20/14 08:35:08 PM
#109940   Ros Thank you for reaching out to GC..I guardiangel 11/20/14 07:50:07 PM
#109939   Its more for medical then public. It's a myersvodka 11/20/14 07:01:37 PM
PostSubject